Incidence, characteristics, and mortality of infective endocarditis in France in 2011

Autoři: S. Sunder aff001;  L. Grammatico-Guillon aff002;  A. Lemaignen aff004;  M. Lacasse aff004;  C. Gaborit aff003;  D. Boutoille aff005;  P. Tattevin aff006;  E. Denes aff007;  T. Guimard aff008;  M. Dupont aff009;  L. Fauchier aff010;  L. Bernard aff002
Působiště autorů: CH de Niort, Service des Maladies Infectieuses et Tropicale, Niort, France aff001;  CHRU de Tours, Unité d’Épidémiologie des données cliniques, EpiDcliC, Tours, France aff002;  Unité Inserm 1259, Université de tours, Tours, France aff003;  CHRU de Tours, Service de Médecine Interne et Maladies Infectieuses, Tours, France aff004;  CHU de Nantes, Service des Maladies Infectieuses et Tropicales, Nantes, France aff005;  CHU de Rennes, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France aff006;  CHU de Limoges, Service des Maladies Infectieuses et Tropicales, Limoges, France aff007;  CH de La Roche sur Yon, Service des Maladies Infectieuses, La Roche sur Yon, France aff008;  CH de Saint Malo, Service des Maladies Respiratoires et Infectieuses, Saint Malo, France aff009;  Equipe d’accueil EA 1275, Université de Tours, Tours, France aff010;  CHRU de Tours, Service de cardiologie, Tours, France aff011
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



We assessed the determinants of mortality in infective endocarditis (IE), using the national hospital discharge databases (HDD) in 2011.


IE stays were extracted from the national HDD, with a definition based on IE-related diagnosis codes. This definition has been assessed according to Duke criteria by checking a sample of medical charts of IE giving a predictive positive value of 86.1% (95% confidence interval (CI): 82.7% - 89.5%). The impact of heart valve surgery on survival has been studied if performed during the initial stay, and over the year of follow-up. Risk factors of in-hospital mortality were identified using logistic regression model for the initial stay and Cox Time-dependent model for the 1-year mortality.


The analysis included 6,235 patients. The annual incidence of definite IEs was 63 cases/million residents. Staphylococci and Streptococci were the most common bacteria (44% and 45%, respectively). A valvular surgery was performed in 20% of cases, but substantial variations existed between hospitals. The in-hospital mortality was 21% (ranging 12% to 27% according to the region of patients), associated with age>70, chronic liver disease, renal failure, S. aureus, P. aeruginosa or candida infection and strokes whereas valvular surgery, a native valve IE or intraveinous drug use (right heart IE) were significantly protective for an initial death. The same factors were associated with the one-year mortality, except for valvular surgery which was associated with a 1.4-fold higher risk of death during the year post IE.


We reported a high IE incidence rate. Valvular surgery was considerably less frequent in this study than in the previous published data (near 50%) whereas mortality was similar. Surgery was associated with higher survival if undergone within the initial stay. There were significant regional differences in frequency of surgery but it did not impact mortality.

Klíčová slova:

Cardiac surgery – Epidemiology – France – Hospitals – Ischemic stroke – Staphylococcus aureus – Streptococcus – Surgical and invasive medical procedures


1. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30: 2369–2413. doi: 10.1093/eurheartj/ehp285 19713420

2. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54: 1230–1239. doi: 10.1093/cid/cis199 22492317

3. Hoen B, Duval X. Clinical practice. Infective endocarditis. N Engl J Med. 2013;368: 1425–1433. doi: 10.1056/NEJMcp1206782 23574121

4. Dzupova O, Machala L, Baloun R, Maly M, Benes J, Czech Infective Endocarditis Working Group. Incidence, predisposing factors, and aetiology of infective endocarditis in the Czech Republic. Scand J Infect Dis. 2012;44: 250–255. doi: 10.3109/00365548.2011.632643 22122645

5. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet. 2015;385: 1219–1228. doi: 10.1016/S0140-6736(14)62007-9 25467569

6. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis. 2011;11: 48. doi: 10.1186/1471-2334-11-48 21345185

7. Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, et al. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther. 2017;7: 27–35. doi: 10.21037/cdt.2016.08.09 28164010

8. Walls G, McBride S, Raymond N, Read K, Coomarasamy C, Morris AJ, et al. Infective endocarditis in New Zealand: data from the International Collaboration on Endocarditis Prospective Cohort Study. N Z Med J. 2014;127: 38–51.

9. Olmos C, Vilacosta I, Fernández-Pérez C, Bernal JL, Ferrera C, García-Arribas D, et al. The Evolving Nature of Infective Endocarditis in Spain: A Population-Based Study (2003 to 2014). J Am Coll Cardiol. 2017;70: 2795–2804. doi: 10.1016/j.jacc.2017.10.005 29191329

10. Østergaard L, Oestergaard LB, Lauridsen TK, Dahl A, Chaudry M, Gislason G, et al. Long-term causes of death in patients with infective endocarditis who undergo medical therapy only or surgical treatment: a nationwide population-based study. Eur J Cardiothorac Surg. 2018;54: 860–866. doi: 10.1093/ejcts/ezy156 29648662

11. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Incidence of Infective Endocarditis Due to Viridans Group Streptococci Before and After the 2007 American Heart Association’s Prevention Guidelines: An Extended Evaluation of the Olmsted County, Minnesota, Population and Nationwide Inpatient Sample. Mayo Clin Proc. 2015;90: 874–881. doi: 10.1016/j.mayocp.2015.04.019 26141329

12. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65: 2070–2076. doi: 10.1016/j.jacc.2015.03.518 25975469

13. Keller K, von Bardeleben RS, Ostad MA, Hobohm L, Munzel T, Konstantinides S, et al. Temporal Trends in the Prevalence of Infective Endocarditis in Germany Between 2005 and 2014. Am J Cardiol. 2017;119: 317–322. doi: 10.1016/j.amjcard.2016.09.035 27816113

14. Sunder S, Grammatico-Guillon L, Baron S, Gaborit C, Bernard-Brunet A, Garot D, et al. Clinical and economic outcomes of infective endocarditis. Infect Dis (Lond). 2015;47: 80–87. doi: 10.3109/00365548.2014.968608 25426997

15. Duval X, Delahaye F, Alla F, Tattevin P, Obadia J-F, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59: 1968–1976. doi: 10.1016/j.jacc.2012.02.029 22624837

16. Grammatico-Guillon L, Baron S, Gettner S, Lecuyer A-I, Gaborit C, Rosset P, et al. Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes. J Hosp Infect. 2012;82: 40–48. doi: 10.1016/j.jhin.2012.04.025 22738613

17. Grammatico L, Baron S, Rusch E, Lepage B, Surer N, Desenclos JC, et al. Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002–2003. Epidemiol Infect. 2008;136: 653–660. doi: 10.1017/S0950268807008850 17568478

18. Grammatico-Guillon L, Baron S, Gaborit C, Rusch E, Astagneau P. Quality assessment of hospital discharge database for routine surveillance of hip and knee arthroplasty-related infections. Infect Control Hosp Epidemiol. 2014;35: 646–651. doi: 10.1086/676423 24799640

19. CLARTE. Consortium Loire-Atlantique-Aquitaine-Rhône-Alpes pour la production d’indicateurs de qualité en sanTE [Internet]. [cited 16 Dec 2013]. Available:

20. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019;380: 415–424. doi: 10.1056/NEJMoa1808312 30152252

21. Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS ONE. 2013;8: e82665. doi: 10.1371/journal.pone.0082665 24349331

22. Ursi MP, Durante Mangoni E, Rajani R, Hancock J, Chambers JB, Prendergast B. Infective Endocarditis in the Elderly: Diagnostic and Treatment Options. Drugs Aging. 2019;36: 115–124. doi: 10.1007/s40266-018-0614-7 30488173

23. Gavazzi G, Krause K-H. Ageing and infection. Lancet Infect Dis. 2002;2: 659–666. 12409046

24. Yoshikawa TT. Perspective: aging and infectious diseases: past, present, and future. J Infect Dis. 1997;176: 1053–1057. doi: 10.1086/516547 9333166

25. Forestier E, Fraisse T, Roubaud-Baudron C, Selton-Suty C, Pagani L. Managing infective endocarditis in the elderly: new issues for an old disease. Clin Interv Aging. 2016;11: 1199–1206. doi: 10.2147/CIA.S101902 27621607

26. Sadighi Akha AA. Aging and the immune system: An overview. J Immunol Methods. 2018;463: 21–26. doi: 10.1016/j.jim.2018.08.005 30114401

27. Kang D-H. Timing of surgery in infective endocarditis. Heart. 2015;101: 1786–1791. doi: 10.1136/heartjnl-2015-307878 26285598

28. Cuervo G, Rombauts A, Caballero Q, Grau I, Pujol M, Ardanuy C, et al. Twenty-Year Secular Trends in Infective Endocarditis in a Teaching Hospital. Open Forum Infect Dis. 2018;5: ofy183. doi: 10.1093/ofid/ofy183 30167435

29. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–Prospective Cohort Study. Archives of internal medicine. 2009;169: 463–473. doi: 10.1001/archinternmed.2008.603 19273776

30. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis. 2005;41: 507–514. doi: 10.1086/431979 16028160

31. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. Eur Heart J. 2010;31: 1890–1897. doi: 10.1093/eurheartj/ehq110 20453066

32. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36: 3075–3128. doi: 10.1093/eurheartj/ehv319 26320109

33. Yombi JC, Yuma SN, Pasquet A, Astarci P, Robert A, Rodriguez HV. Staphylococcal versus Streptococcal infective endocarditis in a tertiary hospital in Belgium: epidemiology, clinical characteristics and outcome. Acta Clin Belg. 2017;72: 417–423. doi: 10.1080/17843286.2017.1309341 28372481

34. Pazdernik M, Kautzner J, Sochman J, Kettner J, Vojacek J, Pelouch R. Clinical manifestations of infective endocarditis in relation to infectious agents: An 8-year retrospective study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160: 298–304. doi: 10.5507/bp.2015.062 26740050

35. N’Guyen Y, Duval X, Revest M, Saada M, Erpelding M-L, Selton-Suty C, et al. Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis. Ann Med. 2017;49: 117–125. doi: 10.1080/07853890.2016.1235282 27607562

36. Rhee C, Gohil S, Klompas M. Regulatory mandates for sepsis care—reasons for caution. N Engl J Med. 2014;370: 1673–1676. doi: 10.1056/NEJMp1400276 24738642

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden